Emre Cörek graduated from Julius-Maximilians-University of Würzburg in Germany with a Bachelor's Degree in Biology in March 2013. He carried out his Bachelor's thesis for six months at the University Hospital of Wuerzburg about the breast cancer radiosensitizing agent NVP-BEZ235 (Dactolisib). The title of his Bachelor`s thesis was “Modulation der Strahlenempfindlichkeit humaner Mammakarzinom-Zelllinien mittels des neuartigen dualen PI3K- und mTOR-Inhibitors NVP-BEZ235. Einfluss von Hypoxie”.

In July 2015 he graduated from the University of Basel in Switzerland with a Master`s Degree in Toxicology. His Master's thesis he accomplished for 10 months at Novartis AG in Basel in Preclinical safety about the renal biomarker Kidney injury molecule-1 (KIM-1). The title of his thesis was “Spatial and temporal patterns of KIM-1 induction in toxic kidney injury in rats”.

In June 2016, Emre Cörek joined the research group of Prof. Dr. J. Huwyler (Pharmaceutical Technology) as a PhD-candidate. His research is focused on nanotoxicology and zebrafish embryo in-vitro assays. He is also involved in the EU Horizon 2020 project NanoREG II for development and implementation of nanoparticle grouping and Safe-by-design approaches within regulatory frameworks together with the Swiss Centre for Applied Human Toxicology (SCAHT).